Download PDF
Endoscopy 2018; 50(10): 1027-1032
DOI: 10.1055/a-0630-1004
Innovations and brief communications
© Georg Thieme Verlag KG Stuttgart · New York

Evaluation of genotoxicity related to oral methylene blue chromoendoscopy

Alessandro Repici
1   Humanitas Clinical and Research Center, Digestive Endoscopy Unit, Division of Gastroenterology, Rozzano, Italy
2   Humanitas University, Department of Biomedical Sciences, Rozzano, Italy
,
Camilla Ciscato
1   Humanitas Clinical and Research Center, Digestive Endoscopy Unit, Division of Gastroenterology, Rozzano, Italy
,
Michael Wallace
3   Division of Gastroenterology and Hepatology, Mayo Clinic Jacksonville, Florida, USA
,
Prateek Sharma
4   Division of Gastroenterology and Hepatology, Veterans Affairs Medical Center and University of Kansas School of Medicine, Kansas City, USA
,
Andrea Anderloni
1   Humanitas Clinical and Research Center, Digestive Endoscopy Unit, Division of Gastroenterology, Rozzano, Italy
,
Silvia Carrara
1   Humanitas Clinical and Research Center, Digestive Endoscopy Unit, Division of Gastroenterology, Rozzano, Italy
,
Milena Di Leo
1   Humanitas Clinical and Research Center, Digestive Endoscopy Unit, Division of Gastroenterology, Rozzano, Italy
2   Humanitas University, Department of Biomedical Sciences, Rozzano, Italy
,
Cesare Hassan
5   Division of Gastroenterology, Nuovo Regina Elena Hospital, Rome, Italy
› Author AffiliationsTRIAL REGISTRATION: Single-center, non-randomized, prospective trial NCT02295774 at clinicaltrials.gov
Further Information

Publication History

submitted 27 November 2017

accepted after revision 16 April 2018

Publication Date:
15 June 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background An oral formulation of methylene blue with colonic delivery (MB-MMX) has been developed to increase detection of colorectal polys during colonoscopy. Traditionally, there have been safety concerns regarding DNA damage when methylene blue is exposed to white light. The aim of this study was to evaluate DNA damage in colonic mucosa after MB-MMX chromoendoscopy.

Methods This was an open-label phase II safety study to assess for genotoxicity on colorectal biopsies of patients undergoing two sequential colonoscopies before and after an oral dose of 200 mg MB-MMX added to their bowel prep. Analysis of a biomarker of double-stranded DNA breaks, γH2AX, was performed on biopsy specimens.

Results Ten patients were included in the study. The mean expression of γH2AX ± 95 % confidence intervals of the 50 biopsies before and after MB-MMX administration were 0.58 ± 0.08 and 0.62 ± 0.09, respectively (P = 0.24). None of the analyzed samples showed excess positive γH2AX expression, confirming the absence of DNA damage on biopsies after methylene blue exposure. No deaths or serious adverse events occurred.

Conclusions An oral dose of 200 mg of MB-MMX did not result in any detectable DNA damage.

Appendix e1 – e3, Fig. e1, e4, Table e1

 

  • References

  • 1 Rahmi G, Lecomte T, Malka D. et al. Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study. Am J Gastroenterol 2015; 110: 288-298
    CrossrefPubMedSearch in Google Scholar
  • 2 Huneburg R, Lammert F, Rabe C. et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 2009; 41: 316-322
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Subramanian V, Mannath J, Ragunath K. et al. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 304-312
    CrossrefPubMedSearch in Google Scholar
  • 4 Subramanian V, Mannath J, Hawkey CJ. et al. High definition colonoscopy vs. standard video endoscopy for the detection of colonic polyps: a meta-analysis. Endoscopy 2011; 43: 499-505
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 ASGE Technology Committee, Wong Kee Song LM, Adler DG et al. Chromoendoscopy. Gastrointest Endosc 2007; 66: 639-649
    CrossrefPubMedSearch in Google Scholar
  • 6 Kamiński MF, Hassan C, Bisschops R. et al. Advanced imaging for detection and differentiation of colorectal neoplasia: ESGE Guideline. Endoscopy 2014; 46: 435-449
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Laine L, Kaltenbach T, Barkun A et al; SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 489-501
    CrossrefPubMedSearch in Google Scholar
  • 8 National Institute for Health and Clinical Excellence. NICE clinical guideline 131. Colorectal cancer. The diagnosis and the management of colorectal cancer. 2011 Available from: https://www.nice.org.uk/Guidance/CG131 Accessed: 30 April 2018
    PubMedSearch in Google Scholar
  • 9 National Toxicology Program. NTP technical report on the toxicology & carcinogenesis studies of methylene blue trihydrate (CAS No. 72220-79-3) in F344/ rats and B6C3F1 mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 2008; 540: 1-224
    PubMedSearch in Google Scholar
  • 10 Davies J, Burke D, Olliver JR. et al. Methylene blue but not indigo carmine causes DNA damage to colonocytes in vitro and in vivo at concentrations used in clinical chromoendoscopy. Gut 2007; 56: 155-156
    CrossrefPubMedSearch in Google Scholar
  • 11 Olliver JR, Hardie LJ, Dexter S. et al. DNA damage levels are raised in Barrett's oesophageal mucosa relative to the squamous epithelium of the oesophagus. Biomarkers 2003; 8: 509-521
    CrossrefPubMedSearch in Google Scholar
  • 12 US Food and Drug Administration. FDA drug safety communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm . Accessed: 8 May 2018
    PubMed
  • 13 Sedelnikova OA, Bonner WM. γH2AX in cancer cells. A potential biomarker for cancer diagnostics prediction and recurrence. Cell Cycle 2006; 5: 2909-2913
    CrossrefPubMedSearch in Google Scholar
  • 14 Porcedda P, Turinetto V, Brusco A. et al. A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry 2009; 6: 508-516
    PubMedSearch in Google Scholar
  • 15 Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003; 63: 4347-4350
    PubMedSearch in Google Scholar
  • 16 Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67-7338
    CrossrefPubMedSearch in Google Scholar
  • 17 National Toxicology Program. Executive summary of safety and toxicity information: methylene blue. CAS Number 61-73-4/7220-79-3. 1990. Available from: https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/methyleneblue_508.pdf Accessed: 30 April 2018
    PubMed
  • 18 Repici A, Di Stefano AF, Radicioni MM. et al. Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers. Contemp Clin Trials 2012; 33: 260-267
    CrossrefPubMedSearch in Google Scholar
  • 19 Kuo LJ, Yang LX. γH2AX – A novel biomarker for DNA double-strand breaks. In Vivo 2008; 22: 305-310
    PubMedSearch in Google Scholar
  • 20 Kiesslich R, Neurath MF. Chromoendoscopy in inflammatory bowel disease. Gastroenterol Clin North Am 2012; 41: 291-302
    CrossrefPubMedSearch in Google Scholar